Scarica l'app Stockscreener
4.85
5.21%
0.24
Dopo l'orario di chiusura:
4.86
0.01
+0.21%
Precedente Chiudi:
$4.61
Aprire:
$4.61
Volume 24 ore:
591.88K
Relative Volume:
0.21
Capitalizzazione di mercato:
$61.31M
Reddito:
-
Utile/perdita netta:
$-30.54M
Rapporto P/E:
-3.129
EPS:
-1.55
Flusso di cassa netto:
$-18.30M
1 W Prestazione:
+4.30%
1M Prestazione:
-30.12%
6M Prestazione:
+702.98%
1 anno Prestazione:
+1,088%
Intervallo 1D:
$4.60
$4.96
Intervallo di 1 settimana:
$4.38
$4.96
Portata 52W:
$0.202
$8.2457
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Nome
Unicycive Therapeutics Inc
Settore
Industria
Telefono
650-384-0642
Indirizzo
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
Confronta UNCY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
4.85 | 58.86M | 0 | -30.54M | -18.30M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-21 | Iniziato | Guggenheim | Buy |
| 2024-04-04 | Iniziato | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Borsa (UNCY) Ultime notizie
Unicycive Therapeutics: Manageable CMC Speed-Bump—Pill-Burden Edge Intact, Buying Opportunity Pre-FDA Decision - AInvest
Unicycive Therapeutics: Manageable CMC Speed BumpPill Burden Edge Intact, Buying (UNCY) - Seeking Alpha
Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology - The Manila Times
Revolutionary Kidney Disease Drug Shows 90% Success Rate with Just 3 Pills Daily, New Study Reveals - Stock Titan
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Is Unicycive Therapeutics Inc. a good long term investmentFree Market Dynamics Reports - jammulinksnews.com
What drives Unicycive Therapeutics Inc. stock priceMarket-beating returns - jammulinksnews.com
Unicycive Therapeutics Inc. Stock Analysis and ForecastFree Smart Trading Workshop - jammulinksnews.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc.UNCY - WV News
Is Unicycive Therapeutics (NASDAQ:UNCY) In A Good Position To Invest In Growth? - Yahoo Finance
What analysts say about Unicycive Therapeutics Inc. stockExceptional market performance - jammulinksnews.com
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Investors to Inquire about Securities Investigation - ACCESS Newswire
Best Stocks for a Post COVID Recovery in India Financial Expert RecommendationsFree Stock Market Trend Analysis - PrintWeekIndia
What analysts say about Palladyne AI Corp. stockRapid growth trajectories - jammulinksnews.com
EWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation With the Schall Law Firm - Business Wire
Published on: 2025-07-18 04:29:16 - Newser
Why Unicycive Therapeutics Inc. stock is on top investor watchlistsDaily Top Gainers - Newser
Why Unicycive Therapeutics Inc. stock attracts strong analyst attentionFast Moving Stock Alerts - Newser
How Unicycive Therapeutics Inc. stock performs during market volatilityReal Chart Play - Newser
What makes Unicycive Therapeutics Inc. stock price move sharplyFree Trading Strategy Suggestions - Newser
Transcript : Unicycive Therapeutics, Inc. Presents at H.C. Wainwright 4th Annual Kidney Virtual Conference, Jul-14-2025 11 - MarketScreener
Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference - 富途牛牛
Pomerantz LLP Investigates Unicycive Therapeutics Securities Fraud Claims. - AInvest
Unicycive Regains Nasdaq Compliance After Stock Split - The Globe and Mail
Unicycive regains Nasdaq compliance after reverse stock split By Investing.com - Investing.com South Africa
Unicycive regains Nasdaq compliance after reverse stock split - Investing.com
Unicycive Therapeutics Regains Compliance with Nasdaq Listing Standards Following Share Price Recovery - Quiver Quantitative
Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire
Unicycive Successfully Maintains Nasdaq Listing Following 1:10 Reverse Stock Split - Stock Titan
Unicycive Therapeutics (NASDAQ:UNCY) Trading 2% Higher – Time to Buy? - Defense World
Unicycive Therapeutics to Participate in H.C. Wainwright 4th Annual Kidney Virtual Conference - Nasdaq
Clinical-Stage Kidney Disease Biotech Unicycive Reveals Latest Therapeutic Progress at Major Healthcare Conference - Stock Titan
Lost Money on Unicycive Therapeutics, Inc. (UNCY)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Unicycive Therapeutics - The Pharma Letter
Unicycive Shares Sink After FDA Issues Response Letter on Kidney Drug Filing - MSN
Ongoing Unicycive Therapeutics, Inc. (UNCY) Investigation: Protect Your RightsContact Levi & Korsinsky - ACCESS Newswire
Unicycive Therapeutics Inc Azioni (UNCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):